WASHINGTON (Reuters) -U.S. President Joe Biden's February biopsy confirmed that a skin lesion removed from his chest was a basal cell carcinoma and all cancerous tissue was successfully removed, White House physician Kevin O'Connor said on Friday.
By Kanishka Singh and Steve Holland
WASHINGTON (Reuters) -U.S. President Joe Biden had a skin lesion removed from his chest in February that was a basal cell carcinoma – a common form of skin cancer – and no further treatment is needed, White House physician Kevin O’Connor said on Friday.
All cancerous tissue was successfully removed, the White House physician said in a letter, adding that Biden will continue dermatologic surveillance as part of his ongoing healthcare but the site had healed.
Last month, doctors declared Biden, 80, healthy and “fit for duty” after a physical examination. They said at the time that a small lesion had been removed from his chest and sent for a biopsy.
O’Connor said in the letter that basal cell carcinoma lesions do not tend to spread or metastasize.
Biden’s health is under close scrutiny as he prepares for an expected run for a second presidential term in 2024. His wife Jill Biden has said he plans to run, although a formal declaration of the president’s intentions has yet to be made.
Whether Biden – already the oldest American president ever – should be the party’s candidate is a source of debate among Democrats.
Biden’s three-hour session with doctors in February at Walter Reed National Military Medical Center in the Washington suburb of Bethesda, Maryland, was his second extensive exam since taking office in January 2021.
(Reporting by Kanishka Singh and Steve Holland in Washington; editing by Diane Craft and Rosalba O’Brien)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: